Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Comparative genome-scale analysis of gene expression profiles in T cell lymphoma cells during malignant progression

S Li1, D T Ross, M E Kadin

  • 1Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Founders 7.06, 3400 Spruce Street, Philadelphia, PA 19104, USA.

The American Journal of Pathology
|April 6, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.

Leukemia·2016
Same author

The Reed-Sternberg Cell, An Activated T-cell? The Evidence Has Come Full Circle.

Leukemia & lymphoma·2016
Same author

KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.

The British journal of dermatology·2016
Same author

CD30-rich transformed mycosis fungoides or anaplastic large cell lymphoma? How to get it right.

The British journal of dermatology·2015
Same author

γδ T-cell-rich variants of pityriasis lichenoides and lymphomatoid papulosis: benign cutaneous disorders to be distinguished from aggressive cutaneous γδ T-cell lymphomas.

The British journal of dermatology·2014
Same author

B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL).

Leukemia·2014

This study compared gene expression in early versus advanced T cell lymphoma. Advanced lymphoma showed altered expression of 180 genes, including those affecting cell growth and drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • T cell lymphoma is a progressive malignancy.
  • Understanding gene expression differences between indolent and aggressive stages is crucial for targeted therapies.

Purpose of the Study:

  • To compare gene expression profiles between early and advanced stages of T cell lymphoma.
  • To identify differentially expressed genes associated with lymphoma progression.

Main Methods:

  • Utilized cDNA microarray to analyze the expression of approximately 8000 genes.
  • Compared gene expression between two clonally related T cell lines from different lymphoma stages.
  • Validated findings using reverse transcription-polymerase chain reaction and Northern blotting.

Related Experiment Videos

Main Results:

  • Identified 180 differentially expressed genes (≥5-fold change) between early and advanced T cell lymphoma stages.
  • 56 genes were up-regulated and 124 genes were down-regulated in advanced lymphoma cells.
  • Up-regulated genes in advanced lymphoma were linked to cell proliferation, survival, and drug resistance; down-regulated genes were associated with cell activation, cell cycle regulation, adhesion, apoptosis, and genome integrity.

Conclusions:

  • Differential gene expression patterns correlate with the clinical behavior of T cell lymphoma.
  • Identified genes provide potential targets for understanding and treating lymphoma progression.